Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431260 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT02431260 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 69 participants.
The verdict
NCT02431260, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
Interventions
- DRUG INCB054329 Monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431260
The ClinicalTrials.gov registry entry for NCT02431260 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB054329 Monotherapy is the first listed.
NCT02431260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431260 about?
NCT02431260 is a clinical study titled "An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies". This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).
What is the current status of trial NCT02431260?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2015-04-14. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT02431260?
The interventions under investigation include: INCB054329 Monotherapy (DRUG).
Who is sponsoring clinical trial NCT02431260?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.